X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (196) 196
index medicus (173) 173
humans (171) 171
chemotherapy (123) 123
female (119) 119
lung cancer (114) 114
male (106) 106
middle aged (94) 94
aged (87) 87
lung neoplasms - drug therapy (84) 84
lung neoplasms - genetics (84) 84
cancer (82) 82
lung cancer, non-small cell (80) 80
lung neoplasms - pathology (80) 80
respiratory system (80) 80
carcinoma, non-small-cell lung - drug therapy (78) 78
mutation (77) 77
gefitinib (68) 68
adult (67) 67
non-small cell lung cancer (67) 67
erlotinib (66) 66
carcinoma, non-small-cell lung - genetics (65) 65
care and treatment (60) 60
open-label (59) 59
carcinoma, non-small-cell lung - pathology (57) 57
adenocarcinoma (56) 56
treatment outcome (49) 49
epidermal growth factor (42) 42
prognosis (42) 42
lung neoplasms - mortality (40) 40
nsclc (40) 40
survival (40) 40
analysis (39) 39
aged, 80 and over (38) 38
disease-free survival (38) 38
cancer therapies (37) 37
antineoplastic combined chemotherapy protocols - therapeutic use (36) 36
cell lung-cancer (36) 36
neoplasm staging (36) 36
1st-line treatment (35) 35
genetic aspects (35) 35
metastasis (35) 35
receptor, epidermal growth factor - genetics (35) 35
tumors (35) 35
respiratory tract diseases (34) 34
research (33) 33
antineoplastic agents - therapeutic use (32) 32
multicenter (32) 32
patients (32) 32
apoptosis (31) 31
carcinoma, non-small-cell lung - mortality (31) 31
hematology, oncology and palliative medicine (31) 31
human necessities (30) 30
hygiene (30) 30
medical or veterinary science (30) 30
neoplasms. tumors. oncology. including cancer and carcinogens (30) 30
cell line, tumor (29) 29
diagnosis (29) 29
expression (28) 28
lung neoplasms (28) 28
medical colleges (28) 28
protein kinase inhibitors - therapeutic use (28) 28
egfr mutation (26) 26
immunotherapy (26) 26
tyrosine kinase inhibitors (26) 26
egfr (25) 25
non-small-cell lung cancer (25) 25
therapy (25) 25
non-small cell lung carcinoma (24) 24
quinazolines - therapeutic use (24) 24
crizotinib (23) 23
docetaxel (23) 23
growth-factor receptor (23) 23
lung neoplasms - metabolism (23) 23
resistance (23) 23
survival analysis (22) 22
kaplan-meier estimate (21) 21
medical prognosis (21) 21
pulmonary/respiratory (21) 21
acquired-resistance (20) 20
adenocarcinoma - genetics (20) 20
identification (20) 20
immunohistochemistry (20) 20
lung cancer, small cell (20) 20
oncology, experimental (20) 20
receptor, epidermal growth factor - antagonists & inhibitors (20) 20
animals (19) 19
development and progression (19) 19
retrospective studies (19) 19
tyrosine (19) 19
carcinoma, non-small-cell lung - metabolism (18) 18
china (18) 18
phase-iii (18) 18
cell biology (17) 17
drug resistance, neoplasm (17) 17
health aspects (17) 17
hospitals (17) 17
paclitaxel (17) 17
antineoplastic agents - pharmacology (16) 16
lung neoplasms - diagnosis (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Translational Lung Cancer Research, ISSN 2218-6751, 2014, Volume 3, Issue 5, pp. 270 - 279
Lung cancer is both the most common diagnosed cancer and the leading cause of cancer related deaths in China. During the past three decades, the incidence and... 
Molecular epidemiology | Lung cancer | Mortality | Incidence | molecular epidemiology | mortality | Review | incidence
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S1449 - S1449
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S86 - S87
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue suppl_7
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 213 - 222
Summary Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free survival compared with pemetrexed and cisplatin for first-line... 
Hematology, Oncology and Palliative Medicine | GEFITINIB | MULTICENTER | SOLID TUMORS | ONCOLOGY | ADENOCARCINOMA | CLINICAL-TRIALS | INHIBITOR | ERBB FAMILY BLOCKER | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - ethnology | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Thailand - epidemiology | Asian Continental Ancestry Group - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Time Factors | Female | Odds Ratio | Republic of Korea - epidemiology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Carcinoma, Non-Small-Cell Lung - ethnology | Linear Models | Logistic Models | Treatment Outcome | China - epidemiology | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Intention to Treat Analysis | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Product development | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 141 - 151
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 8, pp. 735 - 742
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 528 - 538
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 830 - 838
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2016, Volume 34, Issue 16, pp. 1962 - 1963
Journal Article
Zhongguo Fei Ai Za Zhi, ISSN 1009-3419, 12/2015, Volume 18, Issue 12, pp. page - page
近年来,“液态活检”概念异军突起,不仅可以辅助诊断某些类型实体肿瘤,而且能够监测复发,评估疗效及肺癌分子表达,更是无创肿瘤筛查方法。其来源主要分为循环肿瘤细胞(circulating tumor cells, CTCs),循环肿瘤DNA(circulating tumor DNA,... 
Plasma | Flow cytometry | Lung cancer | Genomics | Oncology | Biology | Breast cancer | Metastasis | Gene expression | Cancer therapies | Cell adhesion & migration | Medical prognosis | MicroRNAs | Mutation | Deoxyribonucleic acid--DNA | Tumors | Liquid biopsy | Circulating tumor cells | Ligand-targeted PCR | ctDNA
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S1236 - S1236
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, p. S1236
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S1304 - S1305
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S1246 - S1247
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S1246 - S1247
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 953 - 961
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article